NCT05540028View on ClinicalTrials.gov

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

July 31, 2023

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

IVT PCV-25

25 valent pneumococcal conjugate vaccine

BIOLOGICAL

PCV 20

20 valent pneumococcal conjugate vaccine

Trial Locations (1)

B3K 6R8

Canadian Center for Vaccinology, IWK Health Centre, Halifax

Sponsors

Lead Sponsor

Inventprise Inc.
All Listed Sponsors
collaborator

Canadian Center for Vaccinology

OTHER

collaborator

Vaccine Evaluation Center, Canada

OTHER

collaborator

PATH

OTHER

lead

Inventprise Inc.

INDUSTRY

NCT05540028 - Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter